2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carboxypeptidase
  5. Carboxypeptidase Inhibitor

Carboxypeptidase Inhibitor

Carboxypeptidase Inhibitors (22):

Cat. No. Product Name Effect Purity
  • HY-100788
    2-PMPA
    		Inhibitor 98.0%
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA is applicable to the research of neurological diseases.
  • HY-70005
    CPA inhibitor
    		Inhibitor 99.78%
    CPA inhibitor (Compound 5) (Carboxypeptidase inhibitor) is an orally active competitive carboxypeptidase A (CPA) inhibitor with a Ki value of 0.32 μM. CPA inhibitor blocks the activity of carboxypeptidase A3 (CPA3). CPA activator activates the Wnt/Lrp6/β-catenin signaling pathway. CPA inhibitor reduces epithelial damage. CPA inhibitor is applicable to research related to inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
  • HY-W096171
    D-Dopa
    		Inhibitor 99.67%
    D-Dopa (3-Hydroxy-D-tyrosine) is a potent, orally active, non-competitive and allosteric inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 200 nM. D-Dopa elevates brain dopamine and produce turning behavior in rats. D-Dopa inhibit severe fever with thrombocytopenia syndrome (SFTS) virus infection. D-Dopa can be used for neurological disease and virus infection research.
  • HY-W704574
    Mergetpa
    		Inhibitor
    Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats.
  • HY-W044764
    2-Benzylsuccinic acid
    		Inhibitor 99.83%
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis.
  • HY-165571
    E2072
    		Inhibitor
    E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki of 10 nM. E2072 alleviates established thermal hyperalgesia in a rat model of chronic constriction injury. E2072 prevents oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. E2072 is applicable to research related to neuropathic pain and neuropathy.
  • HY-103345
    2-MPPA
    		Inhibitor 98.0%
    2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM.
  • HY-139840
    GCPII-IN-1
    		Inhibitor 99.83%
    GCPII-IN-1 (Compound 2) is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 can be used in the research of prostate cancer.
  • HY-100788C
    2-PMPA sodium
    		Inhibitor 99.9%
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases.
  • HY-12827
    Sortin1
    		Inhibitor 99.54%
    Sortin1 is a vacuolar protein sorting inhibitor that targets carboxypeptidase Y (CPY). Sortin1 is a soluble and membrane vacuolar marker molecule in plants and yeast.
  • HY-118120
    GEMSA
    		Inhibitor 98%
    GEMSA is a potent inhibitor of enkephalin convertase (Ki=8.8 nM). GEMSA elicites analgesia.
  • HY-139840A
    GCPII-IN-1 TFA
    		Inhibitor 99.58%
    GCPII-IN-1 (Compound 2) TFA is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 TFA can be used in the research of prostate cancer.
  • HY-118391
    Benzoyl-L-phenylalanine
    		Inhibitor 99.68%
    Benzoyl-L-phenylalanine (N-Benzoyl-L-phenylalanine) is a chorisate mutase-prephenate dehydrogenase inhibitor.
  • HY-177760
    PrCP-7414
    		Inhibitor
    PrCP-7414 is a prolyl carboxypeptidase (PRCP) inhibitor. PrCP-7414 blocks PRCP-mediated activation of the IGF1R/HER3 signaling pathway and subsequent AKT activation. PrCP-7414 exhibits pro-apoptotic, anti-tumor and synergistic cytotoxic activities, and inhibits the proliferation and survival of triple-negative breast cancer cells. PrCP-7414 can be used for the research of breast cancer.
  • HY-70003
    Carboxypeptidase G2 (CPG2) Inhibitor
    		Inhibitor 98.02%
    Carboxypeptidase G2 (CPG2) Inhibitor is a novel CPG2 inhibitor with an Ki of 0.3 μM. Carboxypeptidase G2 (CPG2) Inhibitor effectively neutralizes the CPG2 activity in non-tumor sites, allowing for earlier administration of the drug and forming a complementary strategy with antibody clearance strategies. Carboxypeptidase G2 (CPG2) Inhibitor can be used for the study of antibody-directed enzyme prodrug therapy (ADEPT).
  • HY-103344
    ZJ43
    		Inhibitor 99.6%
    ZJ43 is a NAAG peptidase inhibitor and glutamate carboxypeptidase II/III (GCP II/III) inhibitor with human GCP II IC50 of 2.4 nM and Ki of 0.8 nM. ZJ43 blocks N-acetylaspartylglutamate hydrolysis, elevates extracellular N-acetylaspartylglutamate levels, and activates group II metabotropic glutamate receptors (mGluR). ZJ43 can be used for the research of schizophrenia, inflammatory pain, neuropathic pain, and traumatic brain injury.
  • HY-122369
    Histargin
    		Inhibitor
    Histargin is a selective carboxypeptidase B inhibitor with an IC50 of 17 μg/mL and a Ki of 30 μM. Histargin exerts competitive inhibition with substrate, with inhibitory activity abolished by metal cations. Histargin shows no significant inhibitory activity against carboxypeptidase A, aminopeptidase A, or aminopeptidase B.
  • HY-W044764R
    2-Benzylsuccinic acid (Standard)
    		Inhibitor
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis.
  • HY-100788R
    2-PMPA (Standard)
    		Inhibitor
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) Standard is the analytical standard of 2-PMPA (HY-100788). This product is intended for research and analytical applications. 2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases.
  • HY-103345R
    2-MPPA (Standard)
    		Inhibitor
    2-MPPA (Standard) is the analytical standard of 2-MPPA. This product is intended for research and analytical applications. 2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM.